{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Peinetti N"],"funding":["BLRD VA"],"pagination":["e165357"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9711867"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["132(23)"],"pubmed_abstract":["Androgen deprivation therapy (ADT) is the longstanding treatment for advanced prostate cancer (PC) because androgen receptor (AR) is the key therapeutic vulnerability for this disease. Bipolar androgen therapy (BAT) - the rapid cycling of supraphysiologic androgen (SPA) and low serum testosterone levels - is an alternative concept, but not all patients respond and acquired resistance can occur. In this issue of the JCI, Sena et al. developed a gene signature indicative of high AR activity to predict patient response to BAT, including a decline in both serum prostate-specific antigen (PSA) and tumor volume. Preclinical models showed that AR-mediated suppression of MYC, known to drive PC, was associated with decreased cell growth following SPA treatment. Because BAT eventually leads to resis"],"journal":["The Journal of clinical investigation"],"pubmed_title":["Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?"],"pmcid":["PMC9711867"],"funding_grant_id":["I01 BX002773","I01 BX005466"],"pubmed_authors":["Peinetti N","Bilusic M","Burnstein KL"],"additional_accession":[]},"is_claimable":false,"name":"Is androgen receptor activity in metastatic prostate cancer a good biomarker for bipolar androgen therapy?","description":"Androgen deprivation therapy (ADT) is the longstanding treatment for advanced prostate cancer (PC) because androgen receptor (AR) is the key therapeutic vulnerability for this disease. Bipolar androgen therapy (BAT) - the rapid cycling of supraphysiologic androgen (SPA) and low serum testosterone levels - is an alternative concept, but not all patients respond and acquired resistance can occur. In this issue of the JCI, Sena et al. developed a gene signature indicative of high AR activity to predict patient response to BAT, including a decline in both serum prostate-specific antigen (PSA) and tumor volume. Preclinical models showed that AR-mediated suppression of MYC, known to drive PC, was associated with decreased cell growth following SPA treatment. Because BAT eventually leads to resis","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Dec","modification":"2025-04-04T21:00:44.813Z","creation":"2025-02-18T23:35:00.158Z"},"accession":"S-EPMC9711867","cross_references":{"pubmed":["36453547"],"doi":["10.1172/JCI165357"]}}